Innate Pharma S.A. (IPHA)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of  Innate Pharma S.A. (IPHA)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Innate Pharma S.A.(“Innate” or the Company”) (NASDAQ: IPHA). The investigation concerns whether Innate and certain of its officers and/or directors have violated federal securities laws.


On January 9, 2020, Innate announced its decision “to suspend enrollment of new patients” in its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas.  Innate cited “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.”  On this news, Innate’s American depositary receipt price fell sharply during intraday trading on January 9, 2020.

 

If you are aware of any facts relating to this investigation, or purchased Innate shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.